Chinese CDMO WuXi Biologics has announced plans to expand capacity for drug substance and drug product in Germany in response to rising demand for contract manufacturing services.

The company will install a second variable filling line at its Leverkusen site, where existing capacity is about 10 million doses per year, and expects to double capacity at its drug substance facility in Wuppertal, taking output from 12,000 liters to 24,000 liters.

WuXi said the expansion will further enhance its clinical and commercial manufacturing capacities in Europe, strengthening its global dual-sourcing network strategy that ensures materials can be sourced and products manufactured at multiple sites.  

“The investment in our facilities in Germany will add new capacity and enhance our existing manufacturing services, which will strengthen our team’s ability to deliver timely support to our global clients to advance their biologics towards commercialization,” said CEO Chris Chen.